0001654954-24-001964.txt : 20240220 0001654954-24-001964.hdr.sgml : 20240220 20240220161037 ACCESSION NUMBER: 0001654954-24-001964 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240216 FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: tsai chun-hsien CENTRAL INDEX KEY: 0001859363 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41461 FILM NUMBER: 24653359 MAIL ADDRESS: STREET 1: 8880 RIO SAN DIEGO DRIVE STREET 2: SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ainos, Inc. CENTRAL INDEX KEY: 0001014763 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 751974352 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 BUSINESS PHONE: 858-869-2986 MAIL ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 FORMER COMPANY: FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC DATE OF NAME CHANGE: 19960516 4 1 section16.xml PRIMARY DOCUMENT X0508 4 2024-02-16 0001014763 Ainos, Inc. AIMD 0001859363 tsai chun-hsien 8880RIOSANDIEGODR.#800 SANDIEGO CA 92108 true true CEO, PRESIDENT, CHAIRMAN false COMMONSTOCK 2024-02-16 4 A false 26100 0.8693 A 276219 D RSU 2024-02-16 4 C false 26100 D COMMON 26100 161900 D Reference is made to(i) 870,000RSUsthatweregrantedonAugust15,2023, adjusted to 174,000 shares giving effect to the 1 for 5 reverse share split on December 14, 2023, pursuanttotheCompany's2023StockIncentivePlan, with vesting occurring inincrementsof15%on2/15/24,15%on8/15/24,30%on8/15/25,and 40% on 8/15/26 subject to normal and customary termination events; and (ii) 50,000RSUsthatweregrantedpursuanttoanemploymentMandateAgreementdatedMarch17,2022, adjusted to 10,000 shares giving effect to the 1 for 5 reverse share split on December 14, 2023, andundertheCompany's2021StockIncentivePlan,andasamendedbyits2023StockIncentivePlan, with vesting occurringinincrementsof15%on4/24/23and10/24/23,30%on10/24/24and40%on10/24/25,subjecttonormalandcustomaryterminationevents /s/ Chun-Hsien Tsai 2024-02-20